Jay Hagan, Regulus Therapeutics CEO

Sanofi waves the white flag on Reg­u­lus' mi­croR­NA pro­gram tar­get­ing rare kid­ney dis­ease

Sanofi is scrap­ping a drug from a long­time part­ner.

The Big Phar­ma tells End­points News it has halt­ed de­vel­op­ment of lademirsen, dis­cov­ered by Reg­u­lus Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.